Why the study?
The safest and most efficacious P2Y12 inhibitor for older ACS patients who are at both high ischaemic and bleeding risk remains uncertain.
Does the choice of P2Y12 inhibitor (prasugrel, ticagrelor, or clopidogrel) improve ischemic and bleeding outcomes differently in adults >70 years with acute coronary syndromes?
Comparison
Available P2Y12 inhibitors compared against each other
Design
Network meta-analysis of randomized clinical trials
Authors
Loading...
Supports balancing ischemic versus bleeding risks when choosing P2Y12 inhibitors in ACS patients >70 years; extends network meta-analysis rankings to this subgroup.
Does the choice of P2Y12 inhibitor (prasugrel, ticagrelor, or clopidogrel) improve ischemic and bleeding outcomes differently in adults >70 years with acute coronary syndromes?
In older adults (>70 years) with ACS, prasugrel may offer the best ischemic protection while clopidogrel is safest for bleeding, highlighting the need to balance ischemic and bleeding risks when selecting a P2Y12 inhibitor.
Montalto et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: